Homburg Cream & Sugar Study

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

514 participants

Study Classification

OBSERVATIONAL

Study Start Date

2008-02-29

Study Completion Date

2013-08-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to prospectivly analyze the correlation of triglyceride tolerance and glucose tolerance with cardiovascular morbidity and mortality in patients with stable coronary artery disease within 18 months and to determine, whether measurement of triglyceride tolerance can discriminate patients at risk for cardiovascular events.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Coronary Artery Disease Diabetes Metabolic Syndrome Glucose Tolerance Hyperlipidemia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

1

\> 500 consecutive patients with coronary artery disease fulfilling eligibility criteria.

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Stable CAD

Exclusion Criteria

* Acute Coronary Syndrom
* Relevant Arrhythmias
* Severe valvular heart disease
* Decompensated heart failure
* Severe inflammtory disease (infectious, rheumatoid)
* Metabolic diseases (e.g. thyroid)
* Inability to swallow
* Liver or kidney failure
* Lactose intolerance
* Fat intolerance (e.g. chronic pancreatitis, gall stones)
* Malignant Disease
* Psychiatric Diseases (including alcohol / drug abuse)
* Pregnancy

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Ulrich Laufs

Prof. Dr. Ulrich Laufs

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Ulrich Laufs, MD

Role: PRINCIPAL_INVESTIGATOR

University Hospital, Saarland

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

University Hospital Homburg / Saar - Cardiology Department

Homburg, Saarland, Germany

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Germany

References

Explore related publications, articles, or registry entries linked to this study.

Katzmann JL, Werner CM, Stojakovic T, Marz W, Scharnagl H, Laufs U. Apolipoprotein CIII predicts cardiovascular events in patients with coronary artery disease: a prospective observational study. Lipids Health Dis. 2020 May 30;19(1):116. doi: 10.1186/s12944-020-01293-9.

Reference Type DERIVED

PMID: 32473635 (View on PubMed)

Hoffmann MM, Werner C, Bohm M, Laufs U, Winkler K. Association of secreted frizzled-related protein 4 (SFRP4) with type 2 diabetes in patients with stable coronary artery disease. Cardiovasc Diabetol. 2014 Nov 19;13:155. doi: 10.1186/s12933-014-0155-2.